PulseSight Therapeutics is a clinical-stage biotech company developing disruptive, non-viral gene therapies dedicated to ophthalmology, with a current focus on age-related macular degeneration (AMD) including late-stage dry AMD/Geographic atrophy (GA) and wet AMD.
Latest news
October 9, 2026
EarlySight and PulseSight Therapeutics collaborate to add Cellularis® 2 Retinal Imaging to PST-611 Phase 2 Study
October 7, 2026
PulseSight presents PST-611 Phase I new early clinical efficacy data at EURETINA, offering a potential breakthrough approach to treat Dry AMD/Geographic Atrophy
October 2, 2026
RetinAI and PulseSight Therapeutics Expand Collaboration to Support Advancement of PST-611 Gene Therapy Program for Geographic Atrophy into Phase 2a